title: Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
abstract: Survivin and livin are highly expressed in cancer cells and transformed cells, but show little or no expression in normal differentiated tissues. Although human antibody responses to cancer-associated antigens have been detected, the response to livin has not yet been described in lung cancer patients. We examined prevalence of anti-livin antibodies in such patients with a specific enzyme-linked immunosorbent assay (ELISA) using recombinant protein. Using a cutoff value for positivity determined as the mean absorbance +2S.D. for healthy control samples, 19 of 37 lung cancer patients (51.3%) were positive for anti-livin antibodies. Of 31 samples from the same lung cancer patients, 18 (58.1%) were positive for anti-survivin antibodies. When sera from 31 lung cancer patients were assessed simultaneously by anti-survivin and anti-livin ELISAs. Twenty-one patients (71%) were positive for survivin, livin, or both. Intensity of anti-livin antibody responses did not correlate with intensity of anti-survivin responses. Like anti-survivin antibodies, anti-livin antibodies, thus, can be detected in many lung cancer patients. Testing for both antibodies together may prove useful in detecting lung cancer, but more extensive studies are needed to establish the clinical significance of anti-livin antibodies.
authors.affiliation: Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8543, Japan.
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Yagihashi
authors.forename: Koichi
authors.initials: K
authors.lastname: Asanuma
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kobayashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Tsuji
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Shijubo
authors.forename: Shosaku
authors.initials: S
authors.lastname: Abe
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Naoki
authors.initials: N
authors.lastname: Watanabe
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000276:immunology*; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D001323:Autoantibodies / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000276:immunology*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000276:immunology* / Q000503:physiopathology; D008869:Microtubule-Associated Proteins / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology*; D000077022:Survivin
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000912:Antibodies, Neoplasm; D001323:Autoantibodies; C107489:BIRC5 protein, human; C419866:BIRC7 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin